Loading...
Market
What will be the net sales of Rezdiffra in Q4 2024?
2
Resolution / Starting Odds
Less than $20M • 25%
$20M - $30M • 25%
$30M - $40M • 25%
More than $40M • 25%
Madrigal Pharmaceuticals' Q4 2024 financial report
Story
Madrigal's Rezdiffra Launches Strongly with $14.6M Sales
Aug 7, 2024, 08:04 PM
Madrigal Pharmaceuticals has reported a successful launch of its new drug, Rezdiffra, which is the first approved treatment for MASH (Metabolic Associated Steatohepatitis). In the second quarter of 2024, Rezdiffra achieved net sales of $14.6 million, exceeding expectations. The company has secured coverage for more than 50% of commercial patients, with less than 5% requiring a liver biopsy. The launch is expected to gain momentum, with plans to reduce the time to fill prescriptions from 60 days to 30 days by the end of the next quarter. Additionally, Madrigal is preparing for potential EMA approval in 2025.
View original story
Similar markets
Less than $1 billion • 25%
$1 billion - $1.5 billion • 25%
$1.5 billion - $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Below $2.4 billion • 25%
$2.4 billion to $2.5 billion • 25%
$2.5 billion to $2.6 billion • 25%
Above $2.6 billion • 25%
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%
Less than €5 million • 25%
€5 million to €10 million • 25%
€10 million to €20 million • 25%
More than €20 million • 25%
Decrease • 25%
No change • 25%
Increase up to 10% • 25%
Increase more than 10% • 25%
Less than $300M • 33%
$300M - $500M • 33%
More than $500M • 33%
Below €9 billion • 25%
€9 billion - €10 billion • 25%
€10 billion - €11 billion • 25%
Above €11 billion • 25%
Less than $23 billion • 25%
$23-24 billion • 25%
$24-25 billion • 25%
More than $25 billion • 25%